|Articles|August 10, 2022
Financial Modeling From Tufts Center for the Study of Drug Development Demonstrates Substantial Net Benefits to Sponsors Who Use Decentralized Clinical Trials (DCTs) Technology
Author(s)Medable
The data is conclusive, DCTs provide better returns on investment than traditional trials. In fact, new analysis by Tufts CSDD shows DCTs can provide up to 13x ROI in phase III trials & 5x ROI in phase II trials through reductions in clinical trial cycle time, screen failure decreases, and more. Learn more with your free copy of the analysis.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
New AI Oncology Alliance Highlights Industry Push for Scalable Genomics
2
Industry Outlook 2026: Biopharma Braces for Economic Upheaval While Eyeing AI-Driven Transformation (Part 1)
3
CDC Revises Childhood Immunization Schedule, Shifting Demand Dynamics
4
What Are the Benefits of Single-Use in CGT Manufacturing?
5